Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders

This clinical trial is designed as a single-arm, two-center, open-label, prospective study. All participants are enrolled in the standard-dose unrelated umbilical cord blood transplantation group to evaluate the efficacy and safety of unrelated umbilical cord blood transplantation in treating Epstein-Barr virus-associated lymphoproliferative disease.

Trial Details

NCT ID
NCT07381738
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Umbilical cord blood transplantation as treatment of Epstein-Barr virus-associated lymphoproliferative diseases
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • All subjects must meet all of the following criteria:
  • Age range: 14 to 80 years old, inclusive.
  • Diagnosed with an EBV-associated lymphoproliferative disease (including Chronic Active EBV Infection, EBV-associated Hemophagocytic Lymphohistiocyt…
  • Meet at least one of the following disease-specific criteria (see below).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →